Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy
AT-Konsensus · 2024 · Austria
Source and licence
- Authors
- Nicolas Verheyen, Johannes Auer, Nikolaos Bonaros et al.
- Title
- Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy
- Journal
- Wiener Klinische Wochenschrift, 2024
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC11445290
Licence statement of the original publication
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease that is characterized by left ventricular hypertrophy unexplained by secondary causes. Based on international epidemiological data, around 20,000–40,000 patients are expected to be affected in Austria. Due to the wide variety of clinical and morphological manifestations the diagnosis can be difficult and the disease therefore often goes unrecognized. HCM is associated with a substantial reduction in quality of life and can lead to sudden cardiac death, especially in younger patients. Early and correct diagnosis, including genetic testing, is essential for comprehensive counselling of patients and their families and for effective treatment. The latter is especially true as an effective treatment of outflow tract obstruction has recently become available in the form of a first in class cardiac myosin ATPase inhibitor, as a noninvasive alternative to established septal reduction therapies. The aim of this Austrian consensus statement is to summarize the recommendations of international guidelines with respect to the genetic background, pathophysiology, diagnostics and management in the context of the Austrian healthcare system and resources, and to present them in easy to understand algorithms.
Contents of the original publication
The section headings of the original.
- Introduction
- Definition
- Epidemiology
- Pathophysiology
- Left ventricular outflow tract obstruction
- Diagnosis
- Clinical examination and patient history
- Electrocardiography
- Imaging
- Exercise testing
- Heart catheterization and endomyocardial biopsy
- Genetic testing
- Differential diagnosis—HCM phenocopies
- Management
- Atrial fibrillation
- Management of left ventricular outflow tract obstruction
- Prevention of sudden cardiac death
- Heart failure
- Recommendations on physical exercise
- Follow-up and lifetime management of HCM patients
- Echocardiography and cardiac magnetic resonance imaging
- ECG and ECG monitoring
- Cardiopulmonary exercise stress testing
- Genotype-positive, phenotype-negative individuals
- Gaps
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint